Acasti Pharma(ACST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACST Acasti Pharma

Market Closed 10-25 16:00:00 EDT

3.37

+0.00

0.00%

High3.37	Low3.37	Vol0.00
Open3.37	D1 Closing3.37	Amplitude0.00%
Mkt Cap34.17M	Tradable Cap15.66M	Total Shares10.14M
T/O92.82K	T/O Rate0.00%	Tradable Shares4.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ACST","market":"US","secType":"STK","nameCN":"Acasti Pharma","latestPrice":3.37,"timestamp":1729886400000,"preClose":3.37,"halted":8,"volume":0,"delay":0,"floatShares":4646404,"shares":10139861,"eps":-1.101735,"marketStatus":"Market Closed","change":0,"latestTime":"10-25 16:00:00 EDT","open":3.37,"high":3.37,"low":3.37,"amount":92819.927688,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.101735,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730710800000},"marketStatusCode":7,"symbolChange":{"newSymbol":"GRCE","executeDate":"2024-10-28"},"adr":0,"adrRate":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":3.37,"volumeRatio":0},"requestUrl":"/m/hq/s/ACST","defaultTab":"news","newsList":[{"id":"2479194237","title":"OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2479194237","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479194237?lang=en_us&edition=fundamental","pubTime":"2024-10-29 21:47","pubTimestamp":1730209620,"startTime":"0","endTime":"0","summary":"Since the recording of this interview, the company has changed its name to Grace Therapeutics and is now trading under NASDAQ:GRCE.John Viglotti: Hello, and welcome to Virtual Investor Conferences. My name's John Viglotti, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you joined us for our next presentation from Acasti Pharma. John Vandermosten will moderate their session. He's the Senior Biotechnology Analyst with Zacks Small Cap Research. Please note that you can submit questions for the presenter in the box to the left of the slides, and you can also view a company's availability for one-on-one meetings through the \"schedule meetings\" tab on the conference platform. At this point, I'm very pleased to welcome Prashant Kohli. He's the Chief Executive Officer of Acasti Pharma Inc., which trades on NASDAQ under the symbol ACST. Welcome, Prashant and John.John Vandermosten: Great. Thank you for the intro, John. Acasti is a development-stage bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otc-markets-hosts-virtual-investor-134700828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","LENZ","GRCE","ACST"],"gpt_icon":0},{"id":"2478939941","title":"Acasti Pharma Changes Name to Grace Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2478939941","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478939941?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:33","pubTimestamp":1729863210,"startTime":"0","endTime":"0","summary":"Acasti Pharma  said Friday it will change its corporate name to Grace Therapeutics and begin trading on Nasdaq under its new ticker, \"GRCE\" on Oct. 28.The name change reflects the company's origin and brand equity from Grace Therapeutics, which developed GTx-104 before merging with Acasti in 2021.Acasti said it expects to release trial data for GTx-104, an injectable formulation targeting aneurysmal subarachnoid hemorrhage, in early 2025 aiming to submit a new drug application to the US Food and Drug Administration in H1 2025.The company also said it has re-domiciled to the US as a Delaware corporation.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ACST","LENZ","BK4007"],"gpt_icon":0},{"id":"2478185987","title":"BRIEF-Acasti Announces Corporate Name Change  To Grace Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2478185987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478185987?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:07","pubTimestamp":1729861668,"startTime":"0","endTime":"0","summary":"Oct 25  - Acasti Pharma Inc   :   * ACASTI ANNOUNCES CORPORATE NAME CHANGE  TO GRACE THERAPEUTICS, INC.   * ACASTI PHARMA: GRACE THERAPEUTICS TO BEGIN TRADING ON NASDAQ UNDER TRADING SYMBOL \"GRCE\" EFFECTIVE OCT 28Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","BK4007","QID","TQQQ","NQmain","ACST","PSQ","QLD","BK4139","LENZ","SQQQ","MNQmain"],"gpt_icon":0},{"id":"2478989510","title":"Acasti Pharma: Grace Therapeutics to Begin Trading on Nasdaq Under Trading Symbol \"Grce\" Effective Oct 28","url":"https://stock-news.laohu8.com/highlight/detail?id=2478989510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478989510?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:01","pubTimestamp":1729857689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nFWN3M117G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACST"],"gpt_icon":0},{"id":"2478893459","title":"Acasti Announces Corporate Name Change  to Grace Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2478893459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478893459?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:01","pubTimestamp":1729857689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nFWN3M117G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACST"],"gpt_icon":0},{"id":"2478989522","title":"Acasti Announces Corporate Name Change  to Grace Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2478989522","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478989522?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:00","pubTimestamp":1729857600,"startTime":"0","endTime":"0","summary":"Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics. Grace Therapeutics will begin trading on Nasdaq under the trading symbol \"GRCE\" effective October 28, 2024. Virtual Key Opinion Leader Event to be held on November 20th. PRINCETON, N.J., Oct. 25, 2024  -- Acasti Pharma Inc.  , a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage , today announced that it is changing its name to Grace Therapeutics, Inc. . Grace Therapeutics was the name of the company developing GTx-104 prior to its merger with Acasti in 2021. Grace Therapeutics will begin trading on Nasdaq under the trading symbol “GRCE” at the open of the market on October 28, 2024 and all company branding including corporate website will be updated accordingly.GTx-104 is a clinical stage, novel, injectable formulation of nimodipin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/igcc0n0TONBykk8a8oGJXw--~B/aD0xMTQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/24906f14055549a43e3bae5d125037fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/igcc0n0TONBykk8a8oGJXw--~B/aD0xMTQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/24906f14055549a43e3bae5d125037fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acasti-announces-corporate-name-change-120000420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","KOL","LENZ","ACST","BK4139"],"gpt_icon":0},{"id":"2472035478","title":"Acasti Pharma’s Strategic Moves and Shareholder Decisions","url":"https://stock-news.laohu8.com/highlight/detail?id=2472035478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472035478?lang=en_us&edition=fundamental","pubTime":"2024-10-01 04:57","pubTimestamp":1727729852,"startTime":"0","endTime":"0","summary":"Acasti Pharma ( ($ACST) ) has shared an announcement. At a recent shareholder meeting with strong attendance, several key decisions were made affec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acasti-pharmas-strategic-moves-and-shareholder-decisions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acasti-pharmas-strategic-moves-and-shareholder-decisions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACST","BK4007"],"gpt_icon":0},{"id":"2470768185","title":"Acasti Pharma Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2470768185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470768185?lang=en_us&edition=fundamental","pubTime":"2024-09-27 01:43","pubTimestamp":1727372580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 26, 2024 13:43 ET (17:43 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACST"],"gpt_icon":0},{"id":"2470907754","title":"Acasti Pharma Is Maintained at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2470907754","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470907754?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:22","pubTimestamp":1727367720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 26, 2024 12:22 ET (16:22 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACST"],"gpt_icon":0},{"id":"2470736435","title":"Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2470736435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470736435?lang=en_us&edition=fundamental","pubTime":"2024-09-26 20:56","pubTimestamp":1727355365,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Acasti Pharma (ACST – Research Report) today and set a price target of $8.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-acasti-pharma-acst-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-acasti-pharma-acst-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACST"],"gpt_icon":0},{"id":"2470538822","title":"BRIEF-Acasti Announces Completion Of Patient Enrollment In Pivotal Phase 3 Strive-On Safety Trial Of Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2470538822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470538822?lang=en_us&edition=fundamental","pubTime":"2024-09-25 19:32","pubTimestamp":1727263943,"startTime":"0","endTime":"0","summary":"Sept 25 (Reuters) - Acasti Pharma Inc   :   * ACASTI ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PIVOTAL PHASE 3 STRIVE-ON SAFETY TRIAL OF GTX-104Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACST","BK4007"],"gpt_icon":0},{"id":"2470225820","title":"Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 Strive-on Safety Trial of Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2470225820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470225820?lang=en_us&edition=fundamental","pubTime":"2024-09-25 19:30","pubTimestamp":1727263800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240925:nTUA6SHWVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACST","BK4007"],"gpt_icon":0},{"id":"2468464099","title":"Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing","url":"https://stock-news.laohu8.com/highlight/detail?id=2468464099","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468464099?lang=en_us&edition=fundamental","pubTime":"2024-09-20 20:35","pubTimestamp":1726835700,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 20, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held September 19th are now available for online viewing. This event was co-sponsored by Zacks Small-Cap Research.The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company’s resource section.Select companies are accepting 1x1 management meeting requests through September 24th.Virtual Investor Conferences  is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.Providing a real-time investor engagement solution, the VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-123500670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACST","GENFF","CHRO","SQQQ","MNQmain","BK4007","UNCY","PLX","TQQQ","BVAXF","FET","APRE","BK4139","VNRX","EVAX",".IXIC","QLD","AEMD","ADAP","PSQ","QID","NQmain","BK4179"],"gpt_icon":1},{"id":"2468847137","title":"Life Sciences Virtual Investor Forum Agenda Announced for September 19th","url":"https://stock-news.laohu8.com/highlight/detail?id=2468847137","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468847137?lang=en_us&edition=fundamental","pubTime":"2024-09-17 00:07","pubTimestamp":1726502820,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 16, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held September 19th. This event is co-sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.“We’re looking forward to bringing the latest innovators together at the Life Sciences Virtual Investor Forum this Thursday,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. “In collaboration with Zacks Small-Cap Research, this conference will provide an efficient platform for these companies to seamlessly engage their investor base.”Virtual Investor Conferences Contact:John ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/life-sciences-virtual-investor-forum-160700187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","QLD","NQmain","APRE","VNRX","EVAX","QID","BVAXF","BK4588","BK4590","BK4179","ACST","BCLI","GENFF","BK4581","MNQmain","FET","TQQQ","ET","BK4585","ADAP","SQQQ","CHRO","BK4561","BK4144","PSQ","AEMD",".IXIC","UNCY","PLX"],"gpt_icon":1},{"id":"2460221047","title":"Acasti Pharma Appoints Prashant Kohli as CEO with Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2460221047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460221047?lang=en_us&edition=fundamental","pubTime":"2024-08-17 04:37","pubTimestamp":1723840673,"startTime":"0","endTime":"0","summary":"Acasti Pharma (ACST) just unveiled an announcement. Acasti Pharma Inc. has signed an employment agreement with Prashant Kohli as its CEO, offering ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acasti-pharma-appoints-prashant-kohli-as-ceo-with-incentives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acasti-pharma-appoints-prashant-kohli-as-ceo-with-incentives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACST","BK4007"],"gpt_icon":0},{"id":"2459752091","title":"Craig-Hallum Issues a Buy Rating on Acasti Pharma (ACST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459752091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459752091?lang=en_us&edition=fundamental","pubTime":"2024-08-14 20:39","pubTimestamp":1723639144,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Chase Knickerbocker assigned a Buy rating to the stock today. The company’s shares closed yesterday at $2.39. Knickerbocker co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-issues-a-buy-rating-on-acasti-pharma-acst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-issues-a-buy-rating-on-acasti-pharma-acst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACST"],"gpt_icon":0},{"id":"2458067591","title":"Acasti Pharma Inc reports results for the quarter ended in June - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2458067591","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458067591?lang=en_us&edition=fundamental","pubTime":"2024-08-09 22:22","pubTimestamp":1723213328,"startTime":"0","endTime":"0","summary":"* Acasti Pharma Inc    reported a quarterly adjusted loss of 37 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -46 cents.  The ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Acasti Pharma Inc reports results for the quarter ended in June - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACST"],"gpt_icon":0},{"id":"2458627195","title":"Acasti Pharma GAAP EPS of -$0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2458627195","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458627195?lang=en_us&edition=fundamental","pubTime":"2024-08-09 20:16","pubTimestamp":1723205767,"startTime":"0","endTime":"0","summary":"Acasti Pharma press release  : Q1  GAAP EPS of -$0.24.At June 30, 2024 the Company had cash and cash equivalents of $19.4 million, as compared to $23.0 million, as of March 31, 2024. The Company believes it has sufficient cash to support operations into the second calendar quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4138019-acasti-pharma-gaap-eps-of-0_24","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ACST"],"gpt_icon":0},{"id":"2458625645","title":"Acasti Pharma Q1 2025 EPS $(0.24) vs $(0.54) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2458625645","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458625645?lang=en_us&edition=fundamental","pubTime":"2024-08-09 20:09","pubTimestamp":1723205380,"startTime":"0","endTime":"0","summary":"Acasti Pharma Q1 2025 EPS $(0.24) vs $(0.54) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40282099/acasti-pharma-q1-2025-eps-0-24-vs-0-54-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Acasti Pharma Q1 2025 EPS $(0.24) vs $(0.54) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACST"],"gpt_icon":0},{"id":"2458581562","title":"Acasti Pharma Inc: Projected Cash Runway Into Second Calendar Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2458581562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458581562?lang=en_us&edition=fundamental","pubTime":"2024-08-09 20:00","pubTimestamp":1723204801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240809:nTUA8M9JJS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACST","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acasti.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1049},{"period":"3month","weight":0.2458},{"period":"6month","weight":0.1385},{"period":"1year","weight":0.4402},{"period":"ytd","weight":0.1661}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.3257},{"period":"ytd","weight":0.2014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.049456},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.029985},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.04073},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.051963},{"month":5,"riseRate":0.583333,"avgChangeRate":-0.006603},{"month":6,"riseRate":0.5,"avgChangeRate":0.006072},{"month":7,"riseRate":0.5,"avgChangeRate":0.162923},{"month":8,"riseRate":0,"avgChangeRate":-0.174241},{"month":9,"riseRate":0.5,"avgChangeRate":0.089843},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.128874},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.034336},{"month":12,"riseRate":0.727273,"avgChangeRate":0.06653}],"exchange":"NASDAQ","name":"Acasti Pharma","nameEN":"Acasti Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acasti Pharma(ACST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acasti Pharma(ACST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acasti Pharma,ACST,Acasti Pharma股票,Acasti Pharma股票老虎,Acasti Pharma股票老虎国际,Acasti Pharma行情,Acasti Pharma股票行情,Acasti Pharma股价,Acasti Pharma股市,Acasti Pharma股票价格,Acasti Pharma股票交易,Acasti Pharma股票购买,Acasti Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acasti Pharma(ACST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acasti Pharma(ACST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}